Adverse effects (wound pain) · people with pressure ulcers
Hydrogel dressings showed no clear difference in adverse events (wound‐related pain) compared with hydrogel dressings (low certainty).
1 finding from 1 review
Adverse events (soft tissue trauma) · Individuals of any age with no reported disability that might affect toothbrushing (including people wearing orthodontic appliances)
1 finding from 1 review
Serious adverse events (at 52 weeks) · patients with Crohn's disease (with mixed/low disease activity at baseline)
Infliximab showed no clear difference in serious adverse events (at 52 weeks) compared with biosimilar (low certainty).
1 finding from 1 review
Serious adverse events (at 56 weeks) · patients with Crohn's disease (active disease population with clinical response at baseline)
It is very uncertain whether infliximab changes serious adverse events (at 56 weeks) compared with adalimumab (very low certainty).
1 finding from 1 review
Serious adverse events (at 54 weeks) · patients with Crohn's disease (mixed disease activity population with clinical response at baseline)
It is very uncertain whether infliximab changes serious adverse events (at 54 weeks) compared with placebo (very low certainty).
1 finding from 1 review
Adverse events relating to treatment Scale: mild, moderate, severe and total · adults and children with CF with at least one class I mutation (PTC)
1 finding from 1 review
Serious adverse events (52–60 weeks) · people with Crohn's disease
Vedolizumab showed no clear difference in serious adverse events (52–60 weeks) compared with placebo (low certainty).
1 finding from 1 review
Adverse events grade 3 to 5 Range of · participants with advanced or metastatic muscle invasive bladder cancer
Immune checkpoint inhibitors probably leads to lower adverse events grade 3 to 5 Range of compared with any first‐line chemotherapy (moderate certainty).
1 finding from 1 review
Adverse events grade 3 to 5 Range of · participants with advanced or metastatic muscle invasive bladder cancer
Immune checkpoint inhibitors may leads to lower adverse events grade 3 to 5 Range of compared with any second‐line chemotherapy (low certainty).
1 finding from 1 review
Intervention not reported
Number of people with adverse events · people with dementia and mild to moderate pain
1 finding from 1 review
Adverse events: malignancy · primary membranous nephropathy in adults with nephrotic syndrome
It is very uncertain whether oral alkylating agents ± steroids changes adverse events ‐ malignancy at final compared with placebo/no treatment/steroids (very low certainty).
1 finding from 1 review
Adverse events: infection at 3 years · primary membranous nephropathy in adults with nephrotic syndrome
It is very uncertain whether immunosuppressive treatment changes adverse events: infection at 3 years compared with placebo/no treatment/non‐immunosuppressive supportive treatment (very low certainty).
1 finding from 1 review
Adverse events (during intervention) · children/adolescents with post‐traumatic stress and related depressive/anxiety symptoms
1 finding from 1 review
Adverse events ‐ hyperpigmentation ( · people with telangiectasias and reticular veins
Sclerotherapy (STS) probably leads to higher adverse events ‐ hyperpigmentation ( compared with sclerotherapy (any sclerosant) (moderate certainty).
1 finding from 1 review
Adverse events ‐ hyperpigmentation ( · people with telangiectasias and reticular veins
Sclerotherapy probably leads to higher adverse events ‐ hyperpigmentation ( compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events ‐ hyperpigmentation ( · people with telangiectasias and reticular veins
Sclerotherapy (hypertonic saline) probably leads to lower adverse events ‐ hyperpigmentation ( compared with sclerotherapy (any sclerosant) (moderate certainty).
1 finding from 1 review
Adverse events ‐ hyperpigmentation ( · people with telangiectasias and reticular veins
Sclerotherapy (chromated glycerin) showed no clear difference in adverse events ‐ hyperpigmentation ( compared with sclerotherapy (any sclerosant) (low certainty).
1 finding from 1 review
Adverse events ‐ hyperpigmentation ( · people with telangiectasias and reticular veins
Foam showed no clear difference in adverse events ‐ hyperpigmentation ( compared with sclerotherapy (any sclerosant) (low certainty).
1 finding from 1 review
Adverse events ‐ hyperpigmentation ( · people with telangiectasias and reticular veins
Laser probably leads to lower adverse events ‐ hyperpigmentation ( compared with sclerotherapy (moderate certainty).
1 finding from 1 review
Adverse events ‐ hyperpigmentation ( · people with telangiectasias and reticular veins
Laser plus sclerotherapy showed no clear difference in adverse events ‐ Hyperpigmentation ( compared with sclerotherapy (low certainty).
1 finding from 1 review